Biopharma Star Genor Bio Inks Mega Deal to Take its Dual-Targeting Antibody Overseas

Recently, the Hong Kong stock market's innovative pharmaceutical giant - Genor Biological (06998.HK) and the United States biotechnology company TRC2004,Inc. A landmark licensing and equity agreement has been signed, securing a strong overseas strategic partner for GB261, Genor's core R&D project. Under the terms of the agreement, Genor Bio will receive an initial payment of tens of millions of dollars, with the possibility of subsequent milestone payments of up to $443 million, as well as tiered royalties based on net sales in the single-digit to double-digit percentage range.

GB261 is a highly anticipated new CD20/CD3 bisspecific T cell binder (TCE) that presents a unique competitive advantage in the field of innovative drugs. Compared to existing products, GB261 showed significant advantages in reducing potential side effects such as cytokine release syndrome (CRS), while maintaining strong anti-tumor activity in vitro and in vivo experiments. This breakthrough research and development results indicate that GB261 has the potential to open up new treatment paths in the field of treating autoimmune diseases, providing patients with safer and more effective treatment options.

The cooperation with TRC2004 not only reflects the deep strength and commercialization capability of Genor Biology in the field of innovative drug research and development, but also marks the increasing influence of Chinese innovative drug companies in the global market. According to statistics, in the first half of 2024, Chinese pharmaceutical enterprises have completed 60 cross-border business development (BD) transactions, which is far more than the same period in 2023, showing the strong momentum of Chinese innovative pharmaceutical enterprises to actively expand overseas markets and participate in global competition.

With the continuous development and innovation of China's pharmaceutical industry, the competitiveness of domestic innovative drugs in the international market continues to improve. It is foreseeable that in the future, more Chinese innovative pharmaceutical companies will emerge on the global stage, promote the development of the global pharmaceutical industry, and make greater contributions to the health and well-being of global patients.